We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current GUD market cap is 585.77M. The company's latest EPS is CAD -0.1664 and P/E is -34.80.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 49.66M | 199.69M | 243.61M | 297.59M | 331.1M |
| Operating Income | -13.78M | -30.49M | -12.7M | -13.04M | 15k |
| Net Income | 18.03M | 42.07M | 15.68M | -29.89M | -16.84M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 1.31B | 1.04B | 991.89M | 1.05B | 945.49M |
| Total Liabilities | 390.2M | 153.44M | 149.87M | 228.98M | 198.62M |
| Total Equity | 915.11M | 886.24M | 842.02M | 825.86M | 746.87M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | 4.6M | -12.21M | 44.62M | 40.48M | 35.94M |
| Investing | -11.86M | 101.35M | -105.28M | -63.08M | 29.34M |
| Financing | -62.8M | -29.23M | -78.31M | 1.76M | -81M |
| Market Cap | 585.77M |
| Price to Earnings Ratio | -34.80 |
| Price to Sales Ratio | 1.77 |
| Price to Cash Ratio | 9.97 |
| Price to Book Ratio | 0.78 |
| Dividend Yield | - |
| Shares Outstanding | 101.17M |
| Average Volume (1 week) | 67.97k |
| Average Volume (1 Month) | 91.63k |
| 52 Week Change | 20.63% |
| 52 Week High | 5.95 |
| 52 Week Low | 4.35 |
| Spread (Intraday) | 0.15 (2.56%) |
| Company Name | Knight Therapeutics Inc |
| Address |
3400 de maisonneuve w montreal, quebec H3Z 3B8 |
| Website | https://www.gudknight.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
